Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and it's Validation: A Beat AML Project Study

Background: Treatment of acute myeloid leukemia (AML) remains a challenge due to short-lived responses and high rates of relapse. AML cells often possess mutations in kinases (FLT3, JAK2, etc.), resulting in uncontrolled proliferation of neoplastic cells.